If you have been searching for GLP-1 weight loss medications in the UK, you have almost certainly come across Ozempic. It gets more media coverage than Wegovy and Mounjaro combined. And yet it is not in our comparison tool. Here is why — and what this means for you.
Ozempic and Wegovy contain the same active ingredient
Ozempic and Wegovy both contain semaglutide — exactly the same active ingredient. The difference is entirely in what they are licensed for. Ozempic is licensed in the UK for the treatment of type 2 diabetes. Wegovy is licensed for weight management in adults with obesity or overweight. The two products use different dose ranges, different pens, and have different regulatory approvals — but the molecule is identical.
This distinction matters for several reasons. A pharmacy can only legally supply a prescription-only medicine for its licensed indication. A prescriber can issue an off-label prescription in some circumstances, but it is not standard practice for weight management when the weight-management-licensed product (Wegovy) is available.
Why Ozempic got all the attention
Ozempic launched in the UK for type 2 diabetes in 2019, several years before Wegovy arrived. When the dramatic weight loss effects of semaglutide became widely reported — largely driven by social media and celebrity discussion from around 2022 onwards — Ozempic was the brand name people already knew. Some GPs and private prescribers began issuing Ozempic off-label for weight loss, contributing to significant supply shortages that affected people with type 2 diabetes who needed it.
The MHRA and NHS have since issued clear guidance discouraging off-label prescribing of Ozempic for weight loss, given that Wegovy (the licensed product for weight management) is available. In 2024 the MHRA issued a specific safety update on this point.
Can I get Ozempic for weight loss in the UK?
Technically, a prescriber can issue an off-label prescription, and some still do. But it is not recommended practice, and most GPhC-registered online pharmacies now only supply Ozempic against a valid prescription for type 2 diabetes management. If you are looking for semaglutide for weight loss, Wegovy is the correct licensed product — available through private prescription at multiple GPhC-registered pharmacies.
What about Rybelsus?
Rybelsus is an oral tablet form of semaglutide, licensed for type 2 diabetes — not weight loss. An oral Wegovy pill has been approved in the United States and submitted to the MHRA for UK approval, but as of April 2026 it has not yet been authorised here. A MHRA decision is expected in late 2026.
Why it is not in our comparison tool
Our comparison tool lists medications that are licensed in the UK for weight management and that GPhC-registered pharmacies can routinely supply on private prescription for that purpose. Ozempic meets neither criterion for weight loss — it is a diabetes medication. Listing it alongside Wegovy, Mounjaro and Saxenda would be misleading to patients and inaccurate. If and when an oral semaglutide product is licensed in the UK for weight management, we will add it.
If you want semaglutide for weight loss, compare Wegovy prices across all GPhC-registered pharmacies using our tool.